Human genetic analyses revealed that certain genetic variants, particularly in genes such as patatin-like phospholipase domain-containing protein-3 (PNPLA3), transmembrane 6 superfamily 2 human gene (TM6SF2), and glucokinase (hexokinase 4) regulator (GCKR), have been linked to increased susceptibility or protection from NAFLD, influencing liver fat accumulation and disease progression [16,17,18]. This evidence concerns the gene GCKR and metabolic dysfunction-associated steatotic liver disease.